Genomic Visions: Cempra – Oral and Intravenous Fluoroketolid to Improve Community Health

Cempra (CEMP) is a biotechnology company focused on creating a new antibiotic, which may be “the next generation oral and intravenous fluoroketolid.” The company’s main antibiotic, Solithromycin, is currently in a Phase III study for community acquired bacterial pneumonia, as well as a mid-stage trial for gonorrhea. As the report indicates, Cempra will be fulfilling the market need for a new antibiotic, and a demonstrated hole in the bioterror sector. On May 29, the company announced Furthermore, the company announced the receipt of a $58 MM contract to develop antibiotic for pediatric use and biodefense by the Biomedical Advanced Research and Development Authority (BARDA). Further, clinical development remains catalyzed, evidenced by a partnership with Toyoma to further progress clinical development and initiate commercialization activities throughout Japan.

View the full article here (


The comments are closed.